Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02810951 · ClinicalTrials.gov registry record · Phase 1
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 1 study, sponsored by Castle Creek Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02810951: Clinical Trial Phase 1 study, sponsored by Castle Creek Biosciences.
NCT02810951 is a Phase 1 study that was terminated before completion, run by Castle Creek Biosciences. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02810951, a Phase 1 study, was terminated before completion, sponsored by Castle Creek Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FDA OOPD
Primary Outcome
Number of subjects with adverse events.
Interventions
- GENETIC FCX-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
Why NCT02810951 stopped before completion
NCT02810951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which FCX-007 is the first listed.
NCT02810951 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02810951 about?
NCT02810951 is a clinical study titled "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)". The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FD...
What is the current status of trial NCT02810951?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-07-01. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT02810951?
The interventions under investigation include: FCX-007 (GENETIC).
Who is sponsoring clinical trial NCT02810951?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02810951's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI